- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04975711
Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers
October 23, 2023 updated by: Hanmi Pharmaceutical Company Limited
A Randomized, Open-label, Multiple Dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers
A Phase 1 Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers
Study Overview
Detailed Description
A Randomized, Open-label, Multiple dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jin-A Jung, Ph.D.
- Phone Number: 82-2-410-9038
- Email: jajung@hanmi.co.kr
Study Contact Backup
- Name: In-Jin Jang, M.D.
- Phone Number: 82-2-2072-1910
- Email: ijjang@snu.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy volunteers in the age between 19 and 50 years old.
- Body mass index (BMI) in the range of 19 to 28 kg/m2 and weight 55.0kg to 90.0kg.
- After fully hearing and understanding the details of this clinical trial, Subjects who have willingness to sign of informed consent before the screening.
- Subject who are eligible from physical examination, clinical laboratory test by investigators judgment.
Exclusion Criteria:
- Gastrointestinal disorders (gastrointestinal ulcers, gastritis, stomach cramps, gastro-esophageal reflux disease, Crohn's disease or chronic pancreatitis) or gastrointestinal surgery (except for simple cecal or hernia surgery) which may affect the safety and pharmacokinetic evaluation of test drug.
- Subjects who have a history of hypersensitivity or clinically significant hypersensitivity to investigational product or the same component or other drugs (aspirin, antibiotics, etc.).
- Aspartate aminotransferase and alanine aminotransferase exceed 1.5 times the upper limit of normal range from screening laboratory results before randomization.
- Subject who continues to drink (21 units / week, 1 unit = 10 g of pure alcohol) within a month before the screening visit or who cannot abstain during the hospital stay.
- Heavy smoker (>10 cigarettes/day).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test drug(HIP2105) or Reference drug(RLD2104) Sequence 1
Period 1: RLD2104 Period 2: HIP2105
|
Test drug
Reference drug
|
Experimental: Test drug(HIP2105) or Reference drug(RLD2104) Sequence 2
Period 1: HIP2105 Period 2: RLD2104
|
Test drug
Reference drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCtau
Time Frame: 0-24hours
|
0-24hours
|
changed rate from baseline in 24h integrated gastric pH
Time Frame: 0-24hours
|
0-24hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUClast
Time Frame: 0-24hours
|
0-24hours
|
Cmax
Time Frame: 0-24hours
|
0-24hours
|
Tmax
Time Frame: 0-24hours
|
0-24hours
|
t1/2
Time Frame: 0-24hours
|
0-24hours
|
CL/F
Time Frame: 0-24hours
|
0-24hours
|
Vd/F
Time Frame: 0-24hours
|
0-24hours
|
Cmin,ss
Time Frame: 0-24hours
|
0-24hours
|
Cmax,ss
Time Frame: 0-24hours
|
0-24hours
|
t1/2,ss
Time Frame: 0-24hours
|
0-24hours
|
CLss/F
Time Frame: 0-24hours
|
0-24hours
|
Vd,ss/F
Time Frame: 0-24hours
|
0-24hours
|
Duration time with integrated gastric pH>4 / 24hr
Time Frame: 0-24hours
|
0-24hours
|
Median 24 hr gastric pH
Time Frame: 0-24hours
|
0-24hours
|
changed rate from baseline in 24h integrated gastric pH
Time Frame: 0-24hours
|
0-24hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: In-Jin Jang, M.D., Seoul National University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 12, 2021
Primary Completion (Actual)
November 3, 2021
Study Completion (Actual)
November 3, 2021
Study Registration Dates
First Submitted
July 15, 2021
First Submitted That Met QC Criteria
July 15, 2021
First Posted (Actual)
July 23, 2021
Study Record Updates
Last Update Posted (Actual)
October 25, 2023
Last Update Submitted That Met QC Criteria
October 23, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- HM-ESOB-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenActive, not recruiting
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
Spero TherapeuticsCompleted
-
AbbVieCompletedHealthy VolunteerUnited States